- Home
- NODK vs MREO Comparison
NODK vs MREO Comparison
Compare NODK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- MREO
- Stock Information
- Founded
- NODK 1946
- MREO 2015
- Country
- NODK United States
- MREO United Kingdom
- Employees
- NODK N/A
- MREO N/A
- Industry
- NODK Property-Casualty Insurers
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- MREO Health Care
- Exchange
- NODK Nasdaq
- MREO Nasdaq
- Market Cap
- NODK 289.0M
- MREO 286.4M
- IPO Year
- NODK 2017
- MREO N/A
- Fundamental
- Price
- NODK $13.49
- MREO $1.79
- Analyst Decision
- NODK
- MREO Strong Buy
- Analyst Count
- NODK 0
- MREO 5
- Target Price
- NODK N/A
- MREO $7.40
- AVG Volume (30 Days)
- NODK 10.9K
- MREO 1.5M
- Earning Date
- NODK 11-07-2025
- MREO 11-10-2025
- Dividend Yield
- NODK N/A
- MREO N/A
- EPS Growth
- NODK N/A
- MREO N/A
- EPS
- NODK 0.11
- MREO N/A
- Revenue
- NODK $297,973,000.00
- MREO $500,000.00
- Revenue This Year
- NODK N/A
- MREO N/A
- Revenue Next Year
- NODK N/A
- MREO $72.16
- P/E Ratio
- NODK $122.21
- MREO N/A
- Revenue Growth
- NODK N/A
- MREO N/A
- 52 Week Low
- NODK $12.01
- MREO $1.47
- 52 Week High
- NODK $17.24
- MREO $3.94
- Technical
- Relative Strength Index (RSI)
- NODK 53.84
- MREO 43.98
- Support Level
- NODK $13.30
- MREO $1.75
- Resistance Level
- NODK $13.70
- MREO $1.87
- Average True Range (ATR)
- NODK 0.22
- MREO 0.10
- MACD
- NODK 0.02
- MREO -0.00
- Stochastic Oscillator
- NODK 66.03
- MREO 50.00
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).